About Stimuli Technology

The startup develops a non-invasive medical device that utilizes transcutaneous electrical nerve stimulation (TENS) to target the posterior tibial nerve, providing relief for patients suffering from overactive bladder syndrome. This device offers a practical alternative to traditional treatments, enhancing patient quality of life in the French market.

<problem> Overactive bladder syndrome, characterized by urinary urgency, frequency, and nocturia, significantly diminishes patients' quality of life. Traditional treatments often involve medication with potential side effects or invasive procedures, creating a need for practical, non-pharmacological alternatives. </problem> <solution> Tensi+ offers a non-invasive, non-drug based treatment for overactive bladder by utilizing transcutaneous electrical nerve stimulation (TENS) to stimulate the posterior tibial nerve. The Tensi+ device is easily applied to the inner ankle and delivers a 20-minute daily TENS therapy, reducing the symptoms of idiopathic or neurologic overactive bladder. Clinical studies have demonstrated the effectiveness of TENS in reducing urinary urgency, frequency, nocturia, and urge incontinence. The device is designed for autonomous use, allowing patients to continue their daily activities during treatment. </solution> <features> - Non-invasive TENS therapy delivered via a compact, wearable device - Integrated conductive electrodes positioned for targeted stimulation of the posterior tibial nerve - User-friendly design for self-administration at home or on the go - Pre-set 20-minute treatment duration with automatic shut-off - Intensity adjustment with LED indicators for personalized comfort - Rechargeable battery with included USB charging cable - Device is marked CE (class IIa) compliant with the regulation 2017/745 relating to medical devices </features> <target_audience> The primary audience includes individuals experiencing symptoms of overactive bladder, such as urinary urgency, frequent urination, nighttime urination, and urge incontinence, as well as urologists, gynecologists, rehabilitation physicians, and general practitioners seeking a non-pharmacological treatment option for their patients. </target_audience> <revenue_model> Tensi+ is available through a rental model or for purchase after a trial period, with reimbursement available from the French national health insurance (Assurance Maladie) upon prescription. </revenue_model>

What does Stimuli Technology do?

Where is Stimuli Technology located?

Stimuli Technology is based in Boulogne-Billancourt, France.

When was Stimuli Technology founded?

Stimuli Technology was founded in 2017.

How much funding has Stimuli Technology raised?

Stimuli Technology has raised 2740000.

Location

Boulogne-Billancourt, France

Founded

2017

Funding

2740000

Employees

15 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Stimuli Technology

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

tensiplus.com 1K+

Founded 2017 – Boulogne-Billancourt, France

Funding

Estimated Funding

$2M+

Team (15+)

No team information available.

Company Description

Problem

Overactive bladder syndrome, characterized by urinary urgency, frequency, and nocturia, significantly diminishes patients' quality of life. Traditional treatments often involve medication with potential side effects or invasive procedures, creating a need for practical, non-pharmacological alternatives.

Solution

Tensi+ offers a non-invasive, non-drug based treatment for overactive bladder by utilizing transcutaneous electrical nerve stimulation (TENS) to stimulate the posterior tibial nerve. The Tensi+ device is easily applied to the inner ankle and delivers a 20-minute daily TENS therapy, reducing the symptoms of idiopathic or neurologic overactive bladder. Clinical studies have demonstrated the effectiveness of TENS in reducing urinary urgency, frequency, nocturia, and urge incontinence. The device is designed for autonomous use, allowing patients to continue their daily activities during treatment.

Features

Non-invasive TENS therapy delivered via a compact, wearable device

Integrated conductive electrodes positioned for targeted stimulation of the posterior tibial nerve

User-friendly design for self-administration at home or on the go

Pre-set 20-minute treatment duration with automatic shut-off

Intensity adjustment with LED indicators for personalized comfort

Rechargeable battery with included USB charging cable

Device is marked CE (class IIa) compliant with the regulation 2017/745 relating to medical devices

Target Audience

The primary audience includes individuals experiencing symptoms of overactive bladder, such as urinary urgency, frequent urination, nighttime urination, and urge incontinence, as well as urologists, gynecologists, rehabilitation physicians, and general practitioners seeking a non-pharmacological treatment option for their patients.

Revenue Model

Tensi+ is available through a rental model or for purchase after a trial period, with reimbursement available from the French national health insurance (Assurance Maladie) upon prescription.